main_header@2x

Increase Success in Drug Discovery While Reducing Time and Cost with RepliGut®

ABOUT US

Altis Biosystems has created a next-generation in vitro platform that reduces the time and cost of developing safer, more effective drugs.

By replicating native human biology, the intestinal stem cell platform produces more accurate and reproducible data for better clinical trial performance and reduces the need for animal testing.

home_img1_mob

PLATFORM

The RepliGut® Platform

RepliGut® is a unique, stem cell derived platform that recreates the human small intestine and colonic epithelium for more biologically relevant screening of compounds, disease modeling, and microbiome research.

With a scalable platform, actionable data, high throughput screening to test thousands of compounds, and an unrivaled biobank, RepliGut® is the future of in vitro testing during drug development.

SERVICES

The RepliGut® is a reproducible and scalable platform that is suitable for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.

home_icon1

Intestinal Barrier Function

Maintains barrier integrity with high TEER values

Inflammatory Response

Inflammatory Response

Comprised of polarized intestinal cells grown on transwells

home_icon4

GI Toxicity

Screen compounds for 
drug-induced GI toxicity early

home_icon3

Intestinal Drug Disposition

Developed to replace Caco-2 cells (cancer cells) and animals

NEWS AND ARTICLES

August 5, 2021

The Power Of RepliGut® In Vitro Intestinal Stem Cell Models

Both current in vitro and in vivo models used in the development of candidate therapies for the treatment of intestinal diseases have severe limitations. RepliGut®, an in vitro human intestinal epithelial stem cell model, addresses many of these issues and has significant potential to reduce the time and cost of drug development. This model may even help to identify optimal therapies for individual patients.

Read More

April 12, 2021

Developing A Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity

Gastrointestinal (GI) issues are common side effects of many drugs. Anticipating such side effects before clinical trials is limited by a lack of effective models for evaluating preclinical candidates for their potential to cause diarrhea, nausea, and other gut-related side effects. With its RepliGut® in vitro human intestinal model, Altis Biosystems is developing a system that could help pharma companies identify GI toxicity issues early in the drug development process.

Read More

DIGITAL EVENTS

October 4-6, 2021

Immuno-Oncology Summit


Book a Meeting

September 27-30, 2021

Discovery on Target


Book a Meeting

CONTACT US

Have a question? Want to stay informed about Altis, RepliGut, and more platforms currently under development? Send us a message!